AZ, MZ, and the Pulmonary System Response to Hypoxia

Recruiting in Palo Alto (17 mi)

Overseen by Glen E Foster, Ph.D.

Age: 18 - 65

Sex: Male

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: University of British Columbia

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The purpose of this proposal is to compare the physiological effects of acetazolamide (AZ) and methazolamide (MZ) on the control of breathing and hypoxic pulmonary vasoconstriction. The first objective is to assess the effects of AZ and MZ on the control of breathing in normoxia and hypoxia. To achieve this the ventilatory interaction between oxygen and carbon dioxide will be measured and effects compared between placebo, AZ, and MZ conditions. In addition, the isocapnic and poikilocapnic hypoxic ventilatory response and hypercapnic ventilatory response will be measured with each drug. The second objective is to assess the effects of AZ and MZ on the control of the pulmonary vasculature during hypoxia. Pulmonary pressure and cardiac output will be measured during 60 minutes of poikilocapnic hypoxia.

Eligibility Criteria

Inclusion Criteria

18-40 years of age

regularly physically active

male

Treatment Details

Interventions

• Acetazolamide (Carbonic Anhydrase Inhibitor)
• Methazolamide (Carbonic Anhydrase Inhibitor)
• Placebo (Drug)

Participant Groups

Group I: Methazolamide Experimental Treatment 1 Intervention

Participants will be dosed 100mg Methazolamide (p.o.) twice daily separated by a placebo for two days prior to and a single dose on the day of study. The placebo dose is provided to match the dosing schedule between conditions.

Group II: Acetazolamide Experimental Treatment 1 Intervention

Participants will be dosed 250mg Acetazolamide (p.o.) three times per day for two days prior to and a single dose on the day of study.

Group III: Placebo Placebo Group 1 Intervention

Participants will take (p.o.) placebo pills three times per day for two days prior to and a single dose on the day of study.

Acetazolamide is already approved in United States, European Union, Canada for the following indications:

🇺🇸 Approved in United States as Diamox for:

• Glaucoma
• Epilepsy
• Edema
• Altitude sickness

🇪🇺 Approved in European Union as Diamox for:

• Glaucoma
• Epilepsy
• Edema

🇨🇦 Approved in Canada as Diamox for:

• Glaucoma
• Epilepsy
• Edema
• Altitude sickness

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

University of British Columbia Kelowna, Canada

Who Is Running the Clinical Trial?

University of British Columbia Lead Sponsor

References